Fluorescein - BPI Labs LLC

Manufacturer
BPI Labs LLC
Effective date
2026-05-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 22:20:22

Label at a glance#

ProductFluorescein
Active ingredientfluorescein sodium
Label structure14 sections

Indications and uses

Fluorescein Injection 10% (100 mg/mL)  is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)

Dosage and administration

Adult Dose The recommended dosage of Fluorescein Injection 10% (100 mg/mL) is 500 mg via intravenous administration. Pediatric Dose For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 4.54 kg of body weight. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to admini...

Storage and handling

Fluorescein Injection, USP 10%, 500 mg/5 mL (100 mg/mL) of fluorescein sodium is a dark reddish orange, clear solution in a single-dose vial. (NDC 54288-179-10) 5 mL, single dose vials in a package of 10. Store fluorescein injection at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Fluorescein Injection 10% (100 mg/mL)  is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. (1)

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Dosing

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

Adult Dose

The recommended dosage of Fluorescein Injection 10% (100 mg/mL) is 500 mg via intravenous administration.

SPL UNCLASSIFIED SECTION

Pediatric Dose

For children, the dose is 7.7 mg/kg (actual body weight) up to a maximum of 500 mg, via intravenous infusion calculated on the basis of 35 mg for each 4.54 kg of body weight.

2.2 Preparation for Administration

SPL UNCLASSIFIED SECTION

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not mix or dilute with other solutions or drugs.Discard unused portion.

2.3 Administration

SPL UNCLASSIFIED SECTION

Inject the dose (over 5-10 seconds is normally recommended) into the antecubital vein, after taking precautions to avoid extravasation. A syringe, filled with Fluorescein, may be attached to transparent tubing and a 23 gauge butterfly needle for injection. Insert the needle and draw the patient's blood to the hub of the syringe so that a small air bubble separates the patient's blood in the tubing from the fluorescein. With the room lights on, slowly inject the blood back into the vein while watching the skin over the needle tip. If the needle has extravasated, the patient's blood will be seen to bulge the skin and the injection should be stopped before any fluorescein is injected. When assured that extravasation has not occurred, the room light may be turned off and the fluorescein injection completed. Luminescence usually appears in the retina and choroidal vessels in 7 to 14 seconds and can be observed by standard viewing equipment.

Reduction in dose from 500 mg to 200 mg of Fluorescein Injection, 10% may be appropriate in cases when a highly sensitive imaging system e.g., scanning laser ophthalmoscope is used.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Injection:

  • 10%, (500 mg/5 mL) (100 mg/mL) of fluorescein sodium as a dark reddish orange, clear solution in a single-dose vial.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

4.1 Hypersensitivity

SPL UNCLASSIFIED SECTION

Fluorescein Injection is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Respiratory Reactions

SPL UNCLASSIFIED SECTION

Caution should be exercised in patients with a history of allergy or bronchial asthma. An emergency tray should always be available.

If a potential allergy is suspected, an intradermal skin test may be performed prior to intravenous administration, i.e., 0.05 mL injected intradermally to be evaluated 30 to 60 minutes following injection. Given the sensitivity and specificity of skin testing, a negative skin test is not proof that a patient is not allergic to fluorescein.

5.2 Severe local tissue damage

SPL UNCLASSIFIED SECTION

Extravasation during injection can result in severe local tissue damage due to high pH of fluorescein solution. The following complications resulting from extravasation of fluorescein have been noted to occur: Sloughing of the skin, superficial phlebitis, subcutaneous granuloma, and toxic neuritis along the median nerve in the antecubital area. Complications resulting from extravasation can cause severe pain in the arm for up to several hours. When extravasation occurs, the injection should be discontinued and conservative measures to treat damaged tissue and to relieve pain should be implemented. [see Administration (2.3 ) and Adverse Reactions (6.6)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

6.1 Skin and urine discoloration

SPL UNCLASSIFIED SECTION

The most common reaction is discoloration of the skin and urine. Skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours.

6.2 Gastrointestinal Reaction

SPL UNCLASSIFIED SECTION

The next most common adverse reaction is nausea. Vomiting, and gastrointestinal distress have also occurred. A strong taste may develop after injection.

6.3 Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Symptoms and signs of hypersensitivity have occurred. Generalized hives and itching, bronchospasm and anaphylaxis have been reported. [see Contraindications (4.1) and Warnings and Precautions (5.1)]

6.4 Cardiopulmonary Reactions

SPL UNCLASSIFIED SECTION

Syncope and hypotension may occur. Cardiac arrest, basilar artery ischemia, severe shock and death may occur rarely. [see W arnings and Precautions (5.1)]

6.5 Neurologic Reactions

SPL UNCLASSIFIED SECTION

Headache may occur. Convulsions may rarely occur following injection.

6.6 Thrombophlebitis

SPL UNCLASSIFIED SECTION

Thrombophlebitis at the injection site has been reported. Extravasation of the solution at the injection site causes intense pain at the site and a dull aching pain in the injected arm. [see Administration (2.3) and Warnings and Precautions (5.2)].

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Pregnancy Category C. Adequate animal reproduction studies have not been conducted with fluorescein sodium. It is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. Fluorescein sodium should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

Fluorescein sodium has been demonstrated to be excreted in human milk. Caution should be exercised when fluorescein sodium is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Pediatric patients have been included in clinical studies. No overall differences in safety or effectiveness have been observed between pediatric and adult patients.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and other adult patients.

11 DESCRIPTION

DESCRIPTION SECTION

Fluorescein Injection, USP contains fluorescein sodium, a diagnostic aid, in a sterile solution for use intravenously. It is a dark reddish orange clear solution with a pH of 8.3 to 9.8 and an osmolality of 572 to 858 mOsm/kg.


Its chemical name is spiro[isobenzofuran-1 (3H),9'-[9H]xanthene]-3-one,3'6'- dihydroxy, disodium salt. Its molecular weight is 376.27. The active ingredient is represented by the chemical structure:

StructureStructure

Fluorescein Injection, USP 500 mg/5 mL (100 mg/mL) 10% contains:

  • Active ingredient: fluorescein sodium (10% w/v, 100 mg/mL), equivalent to 88.3 mg/mL of fluorescein
  • Inactive ingredients: sodium hydroxide and/or hydrochloric acid may be used to adjust pH (8.3 to 9.8), and Water for Injection.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Fluorescein sodium responds to electromagnetic radiation and light between the wavelengths of 465 to 490 nm and fluoresces, i.e., emits light at wavelengths of 520 to 530 nm. Thus, the hydrocarbon is excited by blue light and emits light that appears yellowish green. Following intravenous injection of fluorescein sodium in an aqueous solution, the unbound fraction of the fluorescein can be excited with a blue light flash from a fundus camera as it circulates through the ocular vasculature, and the yellowish green fluorescence of the dye is captured by the camera. In the fundus, the fluorescence of the dye demarcates the retinal and/or choroidal vasculature under observation, distinguishing it from adjacent  areas/structures.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

SPL UNCLASSIFIED SECTION

Distribution.

Within 7 to 14 seconds after IV administration into the antecubital vein, fluorescein usually appears in the central retinal artery of the eye. Within a few minutes of IV administration of fluorescein sodium, a yellowish discoloration of the skin occurs, which begins to fade 6 to 12 hours after dosing. Various estimates of volume of distribution indicate that fluorescein distributes into interstitial space (0.5 L/kg).

SPL UNCLASSIFIED SECTION

Metabolism.

Fluorescein is metabolized to fluorescein monoglucuronide. After IV administration of fluorescein sodium (14 mg/kg) to 7 healthy subjects, approximately 80% of fluorescein in plasma was converted to glucuronide conjugate after a period of 1 hour post dose.

SPL UNCLASSIFIED SECTION

Excretion.

Fluorescein and its metabolite are mainly eliminated via renal excretion. After IV administration, the urine remains slightly fluorescent for 24 to 36 hours. A renal clearance of 1.75 mL/min/kg and a hepatic clearance (due to conjugation) of 1.50 mL/min/kg have been estimated. The systemic clearance of fluorescein was essentially complete by 48 to 72 hours after administration of 500 mg fluorescein.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There have been no long-term studies done using fluorescein in animals to evaluate carcinogenic potential.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Fluorescein Injection, USP 10%, 500 mg/5 mL (100 mg/mL) of fluorescein sodium is a dark reddish orange, clear solution in a single-dose vial.


(NDC 54288-179-10) 5 mL, single dose vials in a package of 10.


Store fluorescein injection at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Discard unused portion.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

After administration of fluorescein sodium, skin will attain a temporary yellowish discoloration. Urine attains a bright yellow color. Discoloration of the skin usually fades in 6 to 12 hours and usually fades in urine in 24 to 36 hours. [see Warnings and Precautions (6.1)].


Rx only

Manufactured by:
BPI Labs, LLC
12393 Belcher Road S, Suite 450
Largo, FL 33773 USA

LI69I
R-2605
Revised: May 2026

Principal Display Panel – Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel – 5 mL Carton Label

NDC 54288-179-10
Rx Only
Fluorescein Injection, USP 10%
500 mg/5 mL (100 mg/mL) / 10x5 mL sterile Single-dose Vials

Carton LabelCarton Label

Principal Display Panel – Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel – 5 mL Label
NDC 54288-179-01
Rx Only
Fluorescein Injection, USP 10% 500 mg/5 mL (100 mg/mL)

Container LabelContainer Label

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUORESCEIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130354288179010GTIN-13: 0354288179010
EAN-13: 0354288179010
GTIN-12: 354288179010
UPC-A: 354288179010
GTIN storage (14 digits): 00354288179010
Container Label.jpg
BarcodeEAN-130354288179102GTIN-13: 0354288179102
EAN-13: 0354288179102
GTIN-12: 354288179102
UPC-A: 354288179102
GTIN storage (14 digits): 00354288179102
LI179C-10_R-2605_QC_v1_Page_1.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8f43a274-9585-47cb-b427-0eb3e578384dProduct name120250623
4a998fa9-995e-4ea5-97ef-93a559305758Product name120200706
c94ccba7-2a03-4a3e-a891-d62a57340fb2Product name120180215

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54288-179-01Fluorescein5 mL in 1 VIAL, GLASSINJECTION, SOLUTION51
54288-179-10Fluorescein10 in 1 CARTONINJECTION, SOLUTION101

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54288-17954288-179-01, 54288-179-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A220046-001FLUORESCEIN SODIUMFLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-30

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A220046-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A220046-001FLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-30d4dbc9d85df4…
2026-10-15 13:18:302026-09A220046-001FLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-30c2088c7a36db…
2026-09-14 22:38:342026-08A220046-001FLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-3084e616aacf4f…
2026-08-18 06:07:402026-07A220046-001FLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-30caaa826d4ba7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A220046-001FLUORESCEIN SODIUMEQ 500MG BASE/5ML (EQ 100MG BASE/ML)INJECTABLE / INTRAVENOUSAP2026-04-30a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A220046-001AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09A220046-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08A220046-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A220046-001AP1caaa826d4ba7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A220046-001AP1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FluoresceinFLUORESCEINBPI Labs LLC770582e3-c99b-4a02-868c-29309013717e2026-05-01Warnings, Adverse reactionsExact identifier
ndc (package): 54288-179-01
ndc (package): 54288-179-10
ndc (product): 54288-179
ndc11 (package): 54288017901
ndc11 (package): 54288017910
spl id: 5b9c9100-13f7-4eab-a770-339aa885a949
spl set id: 770582e3-c99b-4a02-868c-29309013717e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.